HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Web of Science (2) Citing Articles via Google Scholar Google Scholar Articles by Charlier, C. Articles by Valeyre, D. Search for Related Content PubMed PubMed Citation Articles by Charlier, C. Articles by Valeyre, D.

Evolution of previous sarcoidosis under type 1 interferons given for severe associated disease

¹ Pneumology Dept, and ⁴ Internal Medicine Dept, Avicenne University Hospital, Assistance Publique/Hôpitaux de Paris, Bobigny, ² Hepatology Dept, Jean Verdier University Hospital, Assistance Publique/Hôpitaux de Paris, Bondy, and ³ Multiple Sclerosis Clinic, Dept of Neurology, Tenon University Hospital, Assistance Publique/Hôpitaux de Paris, Paris, France

CORRESPONDENCE: D. Valeyre, Service de Pneumologie, Avicenne Univeristy Hospital, 125 route de Stalingrad, 93009, Bobigny, France. Fax: 33 148955126. E-mail: dominique.valeyre@avc.ap-hop-paris.fr

Keywords: Granulomatosis, hepatitis B virus, hepatitis C virus, interferon- and -ß, multiple sclerosis, sarcoidosis

Received: December 22, 2003
Accepted October 5, 2004

ABSTRACT

Sarcoidosis is a granulomatous disorder with a well-known T helper (Th) type 1 cell commitment and a key pathogenic role of interferon (IFN)-. However, little is known about the influence of type 1 IFNs, such as IFN- and IFN-ß, on the course of previous sarcoidosis.

The aim of this study was to determine whether type 1 IFNs can safely be used in patients with sarcoidosis for severe associated disease.

The present study examined a series of four patients with sarcoidosis, treated by IFN- or IFN-ß for viral hepatitis (three cases) or multiple sclerosis (one case).

IFN was initiated soon after apparent recovery (three cases) or during a worsening phase of sarcoidosis (one case). Hydroxychloroquine was added in the case with active disease. Patients received interferon for 6–24 months and had close monitoring during and after IFN therapy. Interestingly, no recurrence or exacerbation of sarcoidosis had occurred at 4 yrs of follow up. Two patients were cured from viral hepatitis, whilst treatment for another failed. No neurological progression was observed in the remaining patient.

This series suggests that, despite the T helper type 1 phenotype of sarcoid granulomatous reaction, type 1 interferons do not exacerbate sarcoidosis in remission and this makes their use possible if indicated. However, their effect in persistent forms of the disease needs further evaluation.